scholarly journals Punctuated copy number evolution and clonal stasis in triple-negative breast cancer

2016 ◽  
Vol 48 (10) ◽  
pp. 1119-1130 ◽  
Author(s):  
Ruli Gao ◽  
Alexander Davis ◽  
Thomas O McDonald ◽  
Emi Sei ◽  
Xiuqing Shi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Copy Number ◽  
Triple Negative

Abstract 2396: High EGFR gene copy number predicts poor outcome in triple-negative breast cancer.

2013 ◽  
Author(s):  
Heae Surng Park ◽  
Min Hye Jang ◽  
Eun Joo Kim ◽  
Hyun Jeong Kim ◽  
Hee Jin Lee ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Copy Number ◽  
Triple Negative ◽  
Gene Copy Number ◽  
Gene Copy ◽  
Egfr Gene ◽  
Poor Outcome

Abstract P3-07-09: ERRβ copy number and expression in triple negative breast cancer

2018 ◽  
Author(s):  
AI Fernandez ◽  
G Graham ◽  
B Győrffy ◽  
L Cavalli ◽  
A Mahajan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Copy Number ◽  
Triple Negative

DNA copy number alterations and expression of relevant genes in triple-negative breast cancer

2008 ◽  
Vol 47 (6) ◽  
pp. 490-499 ◽  
Author(s):  
Wonshik Han ◽  
Eun-Mi Jung ◽  
Jihyoung Cho ◽  
Jong Won Lee ◽  
Ki-Tae Hwang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Copy Number ◽  
Triple Negative ◽  
Copy Number Alterations ◽  
Dna Copy Number ◽  
Dna Copy Number Alterations

scholarly journals Importance of Copy Number Alterations of FGFR1 and C-MYC Genes in Triple Negative Breast Cancer

2018 ◽  
Vol 0 (0) ◽  
Author(s):  
Milica Nedeljković ◽  
Nikola Tanić ◽  
Tatjana Dramićanin ◽  
Zorka Milovanović ◽  
Snežana Šušnjar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Marker ◽  
Triple Negative Breast Cancer ◽  
Copy Number ◽  
Triple Negative ◽  
Clinical Course ◽  
Copy Number Gain ◽  
Gene Copy ◽  
Copy Number Alterations ◽  
The Impact

Summary Background: Triple negative breast cancer (TNBC) is characterized by aggressive clinical course and is unresponsive to anti-HER2 and endocrine therapy. TNBC is difficult to treat and is often lethal. Given the need to find new targets for therapy we explored clinicopathological significance of copy number gain of FGFR1 and c-MYC. Our aim was to determine the impact of FGFR1 and c-MYC copy number gain on clinical course and outcome of TNBC. Methods: FGFR1 and c-MYC gene copy number alterations were evaluated in 78 archive TNBC samples using TaqMan based quantitative real time PCR assays. Results: 50% of samples had increased c-MYC copy number. c-MYC copy number gain was associated with TNBC in contrast to ER positive cancers. Our results showed significant correlation between c-MYC copy number gain and high grade of TNBCs. This suggests that c-MYC copy number could be an useful prognostic marker for TNBC patients. c-MYC copy number gain was associated with high pTNM stage as well as lobular and medullary tumor subtypes. 43% of samples had increased FGFR1 copy number. No correlations between FGFR1 copy number gain and clinicopathological variables were observed. Conclusions: We identified c-MYC copy number gain as a prognostic marker for TNBC. Our results indicate that c- MYC may contribute to TNBC progression. We observed no significant association between c-MYC and/or FGFR1 copy number status and patient survival.

scholarly journals 1q21.3 amplification modulates therapy sensitivity in Triple Negative Breast Cancer

2020 ◽  
Author(s):  
Ramakanth Chirravuri-Venkata ◽  
Dario Ghersi ◽  
Apar K. Ganti ◽  
Imayavaramban Lakshmanan ◽  
Sanjib Chaudary ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Stratification ◽  
Genetic Marker ◽  
Triple Negative Breast Cancer ◽  
Copy Number ◽  
Triple Negative ◽  
Copy Number Alterations ◽  
Copy Number Status ◽  
Cytotoxic Therapies

AbstractThe contrast in therapy sensitivity and response across triple negative breast cancer (TNBC) patients suggest underlying genotypic heterogeneity. Using publicly available data, we found significant associations between DNA-level copy number alterations of 1q21.3 locus and therapy sensitivity. We show that in spite of their aggressive nature, 1q21.3 amplified tumors are more responsive to commonly used cytotoxic therapies, highlighting the relevance of 1q21.3 copy number status as a genetic marker for risk stratification, therapy selection and response.

scholarly journals Integrated copy number and miRNA expression analysis in triple negative breast cancer of Latin American patients

Oncotarget ◽  
2019 ◽  
Vol 10 (58) ◽  
pp. 6184-6203 ◽  
Author(s):  
Bruna M. Sugita ◽  
Silma R. Pereira ◽  
Rodrigo C. de Almeida ◽  
Mandeep Gill ◽  
Akanksha Mahajan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Latin American ◽  
Expression Analysis ◽  
Triple Negative Breast Cancer ◽  
Mirna Expression ◽  
Copy Number ◽  
Triple Negative

Next generation sequencing reveals CCNE1 amplification as an independent prognostic factor for triple negative breast cancer (TNBC) patients.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 558-558
Author(s):  
Xin Huang ◽  
Huanwen M. Wu ◽  
Changbin Zhu ◽  
Di Shao ◽  
Dan Guo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Copy Number ◽  
Triple Negative ◽  
Genetic Data ◽  
Genetic Alterations ◽  
Clinicopathological Parameters ◽  
Genomic Profiling ◽  
Cyclin E1 ◽  
Comprehensive Genomic Profiling

558 Background: Triple negative breast cancer (TNBC) has the worst prognosis among breast cancer due to the heterogeneity as well as lack of better therapeutic approach. It remains controversial whether BRCA status is the predictor of survival in TNBC. Besides, both germline and somatic mutation may contribute to the prognosis. This study is to explore the potential predictors and therapeutic targets based on genetic data and clinicopathological parameters. Methods: Seventy-five TNBC patients were enrolled with approximately 2:1 based on BRCA status. Genetic data was analysed by comprehensive genomic profiling 508 key cancer related genes. DAVID was applied to perform pathway enrichment analysis of significant enriched genetic alterations. Cox regression model was applied to evaluate disease-free survival (DFS) and overall survival (OS). Immuno-chemistry (IHC) was used to validate clinically meaningful genetic alteration. Results: In this study, 27 germline mutations were detected, including 26 homologous recombination repair (HRR) pathway gene mutations and 1 mismatch repair gene mutation among them 16 BRCA1 mutations and 5 BRCA2 mutations were found. Germline HRR including BRCA1/2 mutation marginally affected DFS ( p = 0.0624 and 0.15, respectively). We found 480 somatic genetic alterations including 110 copy number variations (CNV). The median value of TMB was determined to be 4.1 Muts/Mb which divided 74 TNBC patients into TMB-low (TMB-l) and TMB-high (TMB-h) group. TMB-l group had inferior DFS to TMB-h ( p = 0.0457). CCNE1 (with 5% frequency) copy number gain was specifically enriched in TMB-l group but mutually exclusive with BRCA1/2 mutation. TNBC with CCNE1 gain displayed worse DFS ( p< 0.0001). Cox multivariate regression analysis indicated CCNE1 gain was an independent risk factors for DFS [HR = 13.48 (95% CI 2.62-69.23), p= 0.002)]. Pathway analysis indicated CCNE1 harmed prognosis through regulation of transcription in G1/S phase. Expression of cyclin E1 was validated by IHC, which would be presented later. Conclusions: Comprehensive genomic profiling disclosed various potential prognostic markers for TNBC by integrating clinical characters. Especially, amplified CCNE1 may be a potential prognostic marker and therapeutic target. [Table: see text]

scholarly journals High EGFR gene copy number predicts poor outcome in triple-negative breast cancer

2014 ◽  
Vol 27 (9) ◽  
pp. 1212-1222 ◽  
Author(s):  
Heae Surng Park ◽  
Min Hye Jang ◽  
Eun Joo Kim ◽  
Hyun Jeong Kim ◽  
Hee Jin Lee ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Copy Number ◽  
Triple Negative ◽  
Gene Copy Number ◽  
Gene Copy ◽  
Egfr Gene ◽  
Poor Outcome
Sign in / Sign up

Export Citation Format

Share Document